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Contagious bovine pleuropneumonia (CBPP) caused by Mycoplasma mycoides subsp. mycoides (Mmm) is an
economically very important cattle disease in sub-Saharan Africa. CBPP impacts animal health and poverty of
livestock-dependent people through decreased animal productivity, reduced food supply, and the cost of control
measures. CBPP is a barrier to trade in many African countries and this reduces the value of livestock and the
income of many value chain stakeholders. The presence of CBPP also poses a constant threat to CBPP-free countries
and creates costs in terms of the measures necessary to ensure the exclusion of disease. This opinion focuses on
the biomedical research needed to foster the development of better control measures for CBPP. We suggest that
different vaccine development approaches are followed in parallel. Basic immunology studies and systematic OMICs
studies will be necessary in order to identify the protective arms of immunity and to shed more light on the
pathogenicity mechanisms in CBPP. Moreover a robust challenge model and a close collaboration with African research
units will be crucial to foster and implement a new vaccine for the progressive control of this cattle plague.Table of contents
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11. References1. An African perspective on CBPP
Contagious bovine pleuropneumonia (CBPP) caused by
Mycoplasma mycoides subsp. mycoides (Mmm) was in-
troduced to Africa in the colonial era and subsequently
spread throughout the continent. Control efforts prior
to independence and in the early post-colonial period
were based on stringent movement control combined
with vaccination campaigns supplemented by a policy of
test and slaughter. These early efforts were successful in
suppressing the disease and eventually eradicated CBPP
from a number of countries in Southern Africa. Over
the last few decades Africa has experienced a resurgence
of CBPP and the disease has been reported in many
countries of sub-Saharan Africa (Figure 1). Presently
control of CBPP relies on a live vaccine of limited effi-
cacy and duration of immunity with occasional severe
side effects [2]. OIE-recommended diagnostic tests have
limited sensitivity and are primarily useful at herd but
not at individual level [3]. A policy of strict movementThis is an Open Access article distributed under the terms of the Creative
mons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
al work is properly cited. The Creative Commons Public Domain Dedication
n/zero/1.0/) applies to the data made available in this article, unless otherwise
Figure 1 Occurrence of contagious bovine pleuropneumonia in
Africa between 2010 and 2013. Countries displayed in red have
recorded cases of CBPP. All other countries have been free from the
disease or no reported data. Data were collected from the website
of the World Organization of Animal Health [1].
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to implement in most regions because of public resis-
tance, mobile production systems tailored to highly vari-
able rainfall patterns, fragmented veterinary services and
lack of funds for compensation [4]. Publicly funded mass
vaccination programs have not been sustainable leading
to infrequent or sporadic control. Currently, farmers and
field veterinarians rely heavily on antimicrobials to re-
duce the impact of CBPP, although this practice is often
not permitted under official policy.
Theoretically, the proper application of current vac-
cines could contribute to control programs for CBPP in
many parts of Africa but offers many practical challenges
in terms of the need for near absolute movement con-
trol, continuous annual revaccination and surveillance.
Mariner et al. [4] created an epidemiological model for a
pastoral environment, that included many variables in-
fluencing transmission, and concluded that with the
current live vaccine and diagnostic tests it would be im-
possible to eliminate the pathogen from endemic areas
given the current socio-economic context. While one
can debate the estimates used, the model allows one to
gauge the effect of each parameter on prevalence and
spread of disease. The current situation, characterized by
the spread and reappearance of CBPP in large areas, sup-
ports the findings of the modelling. Mmm is a recently
evolved pathogen with very little sequence variation [5].Genetic diversity will increase in Mmm in case CBPP
expands in Africa as observed during the last decades.
Because of the latter, urgent development and imple-
mentation of better control measures is required.
A better vaccine that protects animals for more than
two years, requires only a single injection, does not need
a cold chain and is not associated with adverse reactions
is key for the progressive control within all regions of
the continent as stated recently at an international CBPP
workshop [5]. However, new tools alone are not enough.
The technological innovations need to be integrated into
effective control strategies and service delivery institu-
tions that harness incentives to drive the participation of
livestock owners and service delivery actors [6].
2. What do we know about immunity to infections
with Mycoplasma mycoides subsp. mycoides?
Experimental findings reported in the CBPP literature
are often contradictory and difficult to integrate in a co-
herent interpretation. Conventional wisdom on CBPP as
reported in the text books is often not supported by do-
cumented evidence, or not rigorously tested for its ac-
curacy. For example, whilst naturally recovered animals
are assumed to be immune, hard evidence from well-
designed experiments to test this belief is lacking. It is
based on field observations that recovered animals do
not become re-infected, but there is no systematic infor-
mation on what is understood by “infected and reco-
vered”, nor what percentage of recovered cattle would
be immune, or for how long.
Injection with the current live vaccine results in pro-
tection of up to one year but does not prevent the devel-
opment of pathomorphological lesions after challenge
suggesting induction of limited immunity. Unfortunately,
there is no reported method to consistently induce solid
immunity against Mmm infections or rigorous evidence
that such a state in fact exists. The current understan-
ding of CBPP immunology does not allow us to name
the main protective mechanism. For instance antibody
transfer experiments carried out in the past are difficult
to interpret [7], as the amount and specificity of an-
tibodies present in the donor and recipient were not
known and total serum, not purified, antibodies was
transferred. Different views about the protective role
of CD4+ T cells in the course of a primary infection
were published [8,9]. Therefore it is necessary to carry out
basic studies that assess the role of T cells and antibodies
from protected animals, such as after vaccination, in an
unambiguous way.
3. A better CBPP challenge model is needed
A suboptimal challenge model that requires relatively
large animal numbers hampers CBPP research. The
current intubation model should be replaced by a more
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comparison of data from different experimental infec-
tions. In-contact infections, which resemble the natural
course of infection, do not allow the simultaneous in-
duction of CBPP in all animals to be infected, which
limits its value as a tool in comparative trials.
We urge the establishment of a robust uniform chal-
lenge bovine model for CBPP (specification of minimal
infective dose, host age and breed, and Mycoplasma
isolates) so that data can be better compared between
laboratories. We suggest exploring the use of Myco-
plasma-containing aerosols for infection since this re-
sembles the natural route of infection best. In parallel
we believe that the development of a caprine infec-
tion model, which will enable us to test well-targeted
mutants of the closely related pathogen Mycoplasma
mycoides subsp. capri will be beneficial for basic proof of
concept studies in CBPP. The establishment of both
models will be more cost effective and foster CBPP
research outcomes worldwide.
4. Empirical vaccine approach versus design of a
rational vaccine?
The current live vaccines based on the T1 strain have
limited efficacy and do only allow improvements though
genetic manipulation of the strain or the introduction of
alternative media to foster different expression patterns.
The T1/44 strain has been reported to be attenuated
through 44 passages in eggs [10], but it can still cause
disease when applied directly into the lungs [11], the
normal route for provoking an experimental infection.
The Chinese vaccine strain, BEN-1, which has been ap-
plied for the progressive control of CBPP in China [12]
requires evaluation in African cattle breeds challenged
by African isolates in order to compare its efficacy with
the current live vaccine T1/44.
The generation of a genetically modified live vaccine is
theoretically possible but implementation of the vaccine
in the field would be challenging because of expected
delays by biosafety and veterinary regulatory bodies to
use such an organism throughout Africa.
Empirical approaches based on individual combina-
tions of antigens or antigen preparations including a
bacterin type of vaccine are easy to assess in terms of
their efficacy and do not require detailed knowledge on
the protective arm of immunity or the pathogenicity
mechanisms involved. Their read out is simple: protec-
tion or no protection after challenge. But if a combi-
nation of individual antigens for incorporation into a
subunit vaccine is needed, even Mycoplasma mycoides
subsp. mycoides, with a genome size of about 1 Mb, still
offers ample combinations of immunogens to assess in
costly challenge experiments without prior selection. Al-
though one could argue that the latter is also a rationalapproach to vaccine development we suggest reserving
the term rational for an approach as described below.
Reverse vaccinology and the “OMICS” era offer tools
to narrow down the number of molecules to be tested,
through identification of virulence traits using compara-
tive genomics and in vivo proteomics and transcripto-
mics, and we urge that such an approach is followed in
parallel.
Several arguments support the initiation of a rational
strategy, despite the fact that systematic, empirical ap-
proaches might provide quick answers. The latter are al-
ways based on an unproven hypothesis, such as that
antibody titres correlate with immunity or that protec-
tive antigens are protein in nature. Immunization with a
single lipoprotein antigen resulted in enhanced path-
ology after challenge, suggesting adverse vaccine out-
comes [13]. The same was found in experiments for a
subunit vaccine to M. bovis [14]. These observations in-
dicate that such antigens should be avoided in a vaccine
and preference should be given to a (subunit) vaccine
consisting of protective antigens only. Similarly, some
host responses might exacerbate disease rather than pro-
tect. Alternatively, a response to a particular antigen
might fail to detect the appropriate epitope that could
induce protection, such as the cattle response against
GlpO [15]. Up till now, empirical approaches have not
delivered the promised vaccine.
5. What knowledge is needed to foster the
development of a better vaccine?
5.1 Establish a method to induce solid immunity
It is desirable to establish a reproducible method to
induce solid immunity against Mycoplasma mycoides
subsp. mycoides. Validating the extent and the nature
of immunity in fully recovered natural infections or
animals immunized with the current live vaccine will
be a good starting point. A better challenge model, as
discussed above, will help us to read out such an im-
mune state.
5.2 Identify protective host immune responses
Generation of solidly immune animals, if possible, will
be essential to identify the protective responses that pre-
vent clinical disease. Since there is no rodent model for
CBPP, direct experiments on ruminants have to be carried
out to derive evidence. Experiments such as antibody
transfer, depletion of specific leukocyte subpopulations,
neutralization of immune functions or cytokines should
be employed to classify particular responses during a
course of CBPP. Having a better understanding of the type
of responses that provide protection will allow us to de-
sign a vaccine via tailored adjuvants and delivery systems
that specifically induces those responses. The research
community should make an effort to characterize the
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these responses prime subsequent adaptive immune
response and might give insight into the pathogenesis
during CBPP.
We also suggest looking in more detail into the pro-
tective immunity mechanisms of the bacterin type of
the vaccine against contagious caprine pleuropneumo-
nia (CCPP), which clinically resembles CBPP. This vaccine
has proven to confer immunity [16] against Mycoplasma
capricolum subsp. capripneumoniae, which is also a mem-
ber of the so called “Mycoplasma mycoides cluster” and
phylogentically related to Mmm [17]. Understanding the
protective mechanisms induced by the CCPP vaccine may
inform us about the bovine situation.5.3 Understand host-pathogen interaction
Having an understanding of the mechanisms and the
sequence of molecular events that lead to disease are im-
portant to identify virulence traits and protective an-
tigens. The published sequence of the type strain PG1
[18] was a milestone in CBPP research and enabled sub-
sequent downstream applications such as proteomics
[19,20] and reverse vaccinology. Virulence differences in
African and European isolates have been reported [21]
and enabled the identification of a metabolic enzyme as
virulence trait in the past [22].
Systematic OMICs studies such as genomics, tran-
scriptomics, proteomic, lipidomics and glycomics should
be carried out and integrated into systems biology ap-
proaches in order to better understand the pathogen, the
host and their interactions. Preliminary efforts have been
made in that direction, such as monitoring the kine-
tics of antibody specificities using bead assays [20] and
the characterization of in vitro surface core proteome
[23]. These data are now available and will contribute
to detailed information regarding individual antibody
responses to help identify protective or pathological
responses.
Finally, we need to investigate the nature of host-
pathogen interactions in a more systematic way and iden-
tify interactions that correlate with disease severity.
OMICs data are likely to provide more insight into the
molecules that shape pathogenicity, virulence and host
specificity. Recently, techniques for the targeted mutage-
nesis of members of the “M. mycoides cluster” have been
developed as part of synthetic biology efforts [24] and
awaiting their application in CBPP research. In vitro as-
says such as those that measure adhesion to different cell
lines of the respiratory tract and those that examine in-
teractions with host cells such as macrophages have
to be established and will allow the screening for
molecules that mediate host-pathogen interactions, using
targeted mutagenesis.5.4 Understand the epidemiology of CBPP
Better epidemiological data for CBPP are needed in
order to integrate the specifications of the current and
future control measures (vaccines and diagnostics) in a
model that is more robust with less unknown parame-
ters than the current one. Important parameters include
the rate of transmission, and the effect of antimicrobial
treatments and vaccination on transmission. Such expe-
riments are costly but needed in order to have a cohe-
rent epidemiological model which advices policy makers
in Africa with respect to decisions that underpin a
progressive disease control.6. Research carried out in developed and
developing countries
We believe that a partnership of laboratories in develop-
ing and developed countries will be essential to tackle
CBPP. Research goals will be more easily achieved by
performing in vivo experiments in Africa. Past experi-
ments infecting mice are in our opinion of little value, as
the mycoplasmas do not induce disease, and are not bet-
ter than culturing mycoplasma in vitro, offering little
promise for the future. The reduced cost of experiments
in Africa makes it possible to use larger numbers of ani-
mals, while the endemicity of the pathogen reduces the
risks associated with pathogen escape into a naïve popu-
lation. Further, working in endemic areas provides access
to the genetic diversity of cattle that are at risk and
avoids the need for shipping samples, which may affect
measurements from subsequent experiments involving
live host cells. Finally, it also builds capacity in the re-
gion helping to support laboratories on the continent
that will be needed in the future to implement the new
products.
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